A Multi-part, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD0715 in Healthy Human Volunteers and Participants With Axial Spondyloarthritis
Latest Information Update: 26 Aug 2025
At a glance
- Drugs GRWD 0715 (Primary)
- Indications Axial spondyloarthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms EAST-1
- Sponsors Grey Wolf Therapeutics
Most Recent Events
- 08 Aug 2025 Status changed from not yet recruiting to recruiting.
- 11 Jul 2025 New trial record